Co-Authors
This is a "connection" page, showing publications co-authored by AMY B HEIMBERGER and SHOUHAO ZHOU.
Connection Strength
1.746
-
Window-of-opportunity clinical trial of pembrolizumab in patients with recurrent glioblastoma reveals predominance of immune-suppressive macrophages. Neuro Oncol. 2020 04 15; 22(4):539-549.
Score: 0.182
-
Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target. J Clin Invest. 2019 01 02; 129(1):137-149.
Score: 0.165
-
Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026.
Score: 0.164
-
Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic Lineage in Adult Gliomas. J Neuropathol Exp Neurol. 2018 06 01; 77(6):437-442.
Score: 0.160
-
Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology. 2018; 7(4):e1412909.
Score: 0.156
-
Ependymomas overexpress chemoresistance and DNA repair-related proteins. Oncotarget. 2018 Jan 30; 9(8):7822-7831.
Score: 0.155
-
Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. Neuro Oncol. 2017 Aug 01; 19(8):1047-1057.
Score: 0.151
-
Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016 10; 18(10):1357-66.
Score: 0.140
-
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype. JCI Insight. 2016; 1(2).
Score: 0.136
-
Tipping a favorable CNS intratumoral immune response using immune stimulation combined with inhibition of tumor-mediated immune suppression. Oncoimmunology. 2016 May; 5(5):e1117739.
Score: 0.135
-
MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints. Neuro Oncol. 2016 05; 18(5):639-48.
Score: 0.134
-
Multiplatform profiling of meningioma provides molecular insight and prioritization of drug targets for rational clinical trial design. J Neurooncol. 2018 Sep; 139(2):469-478.
Score: 0.040
-
Targeting 4-1BB costimulation to the tumor stroma with bispecific aptamer conjugates enhances the therapeutic index of tumor immunotherapy. Cancer Immunol Res. 2014 Sep; 2(9):867-77.
Score: 0.030